At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 35 enrolled
Drug / intervention
PF-06882961 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, OPEN-LABEL, TWO-PART STUDY TO EVALUATE THE EFFECT OF TWO STEADY-STATE DOSE LEVELS OF PF-06882961 ON THE PHARMACOKINETICS OF SINGLE ORAL DOSES OF ATORVASTATIN AND MIDAZOLAM IN HEALTHY ADULTS AND AN ORAL CONTRACEPTIVE IN HEALTHY POST-MENOPAUSAL FEMALES
In Brief
A Phase 1 clinical trial evaluating PF-06882961, Atorvastatin, and 2 other interventions for Healthy Adults. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult male and female participants (Part A), or an OC in healthy PM female participants (Part B).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Adults
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartOct 2021
First PostedOct 2021
Primary CompletionJul 2022
TodayJul 2026
First PostedOct 26, 2021
Enrollment StartOct 25, 2021
Primary CompletionJul 6, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.7 years ago
Interventions
PF-06882961drug
Tablets
Atorvastatindrug
Tablets
Midazolamdrug
Syrup
Levonorgestrel & Ethinyl Estradioldrug
Tablet